Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine : An American Headache Society position statement update
© 2024 American Headache Society..
OBJECTIVE: To provide a position statement update from The American Headache Society specifically regarding therapies targeting calcitonin gene-related peptide (CGRP) for the prevention of migraine.
BACKGROUND: All migraine preventive therapies previously considered to be first-line treatments were developed for other indications and adopted later for migraine. Adherence to these therapies is often poor due to issues with efficacy and tolerability. Multiple new migraine-specific therapies have been developed based on a broad foundation of pre-clinical and clinical evidence showing that CGRP plays a key role in the pathogenesis of migraine. These CGRP-targeting therapies have had a transformational impact on the management of migraine but are still not widely considered to be first-line approaches.
METHODS: Evidence regarding migraine preventive therapies including primary and secondary endpoints from randomized placebo-controlled clinical trials, post hoc analyses and open-label extensions of these trials, and prospective and retrospective observational studies were collected from a variety of sources including PubMed, Google Scholar, and ClinicalTrials.gov. The results and conclusions based upon these results were reviewed and discussed by the Board of Directors of The American Headache Society to confirm consistency with clinical experience and to achieve consensus.
RESULTS: The evidence for the efficacy, tolerability, and safety of CGRP-targeting migraine preventive therapies (the monoclonal antibodies: erenumab, fremanezumab, galcanezumab, and eptinezumab, and the gepants: rimegepant and atogepant) is substantial, and vastly exceeds that for any other preventive treatment approach. The evidence remains consistent across different individual CGRP-targeting treatments and is corroborated by extensive "real-world" clinical experience. The data indicates that the efficacy and tolerability of CGRP-targeting therapies are equal to or greater than those of previous first-line therapies and that serious adverse events associated with CGRP-targeting therapies are rare.
CONCLUSION: The CGRP-targeting therapies should be considered as a first-line approach for migraine prevention along with previous first-line treatments without a requirement for prior failure of other classes of migraine preventive treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Headache - 64(2024), 4 vom: 15. Apr., Seite 333-341 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Charles, Andrew C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.04.2024 Date Revised 23.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/head.14692 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369557603 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369557603 | ||
| 003 | DE-627 | ||
| 005 | 20240424232032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/head.14692 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1385.xml |
| 035 | |a (DE-627)NLM369557603 | ||
| 035 | |a (NLM)38466028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Charles, Andrew C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine |b An American Headache Society position statement update |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2024 | ||
| 500 | |a Date Revised 23.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 American Headache Society. | ||
| 520 | |a OBJECTIVE: To provide a position statement update from The American Headache Society specifically regarding therapies targeting calcitonin gene-related peptide (CGRP) for the prevention of migraine | ||
| 520 | |a BACKGROUND: All migraine preventive therapies previously considered to be first-line treatments were developed for other indications and adopted later for migraine. Adherence to these therapies is often poor due to issues with efficacy and tolerability. Multiple new migraine-specific therapies have been developed based on a broad foundation of pre-clinical and clinical evidence showing that CGRP plays a key role in the pathogenesis of migraine. These CGRP-targeting therapies have had a transformational impact on the management of migraine but are still not widely considered to be first-line approaches | ||
| 520 | |a METHODS: Evidence regarding migraine preventive therapies including primary and secondary endpoints from randomized placebo-controlled clinical trials, post hoc analyses and open-label extensions of these trials, and prospective and retrospective observational studies were collected from a variety of sources including PubMed, Google Scholar, and ClinicalTrials.gov. The results and conclusions based upon these results were reviewed and discussed by the Board of Directors of The American Headache Society to confirm consistency with clinical experience and to achieve consensus | ||
| 520 | |a RESULTS: The evidence for the efficacy, tolerability, and safety of CGRP-targeting migraine preventive therapies (the monoclonal antibodies: erenumab, fremanezumab, galcanezumab, and eptinezumab, and the gepants: rimegepant and atogepant) is substantial, and vastly exceeds that for any other preventive treatment approach. The evidence remains consistent across different individual CGRP-targeting treatments and is corroborated by extensive "real-world" clinical experience. The data indicates that the efficacy and tolerability of CGRP-targeting therapies are equal to or greater than those of previous first-line therapies and that serious adverse events associated with CGRP-targeting therapies are rare | ||
| 520 | |a CONCLUSION: The CGRP-targeting therapies should be considered as a first-line approach for migraine prevention along with previous first-line treatments without a requirement for prior failure of other classes of migraine preventive treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CGRP | |
| 650 | 4 | |a calcitonin gene‐related peptide‐targeting therapies | |
| 650 | 4 | |a migraine | |
| 650 | 4 | |a position statement | |
| 650 | 4 | |a prevention | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a erenumab |2 NLM | |
| 650 | 7 | |a I5I8VB78VT |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a fremanezumab |2 NLM | |
| 650 | 7 | |a eptinezumab |2 NLM | |
| 650 | 7 | |a 8202AY8I7H |2 NLM | |
| 700 | 1 | |a Digre, Kathleen B |e verfasserin |4 aut | |
| 700 | 1 | |a Goadsby, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Robbins, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Hershey, Andrew |e verfasserin |4 aut | |
| 700 | 0 | |a American Headache Society |e verfasserin |4 aut | |
| 700 | 1 | |a Charles, Andrew C |e investigator |4 oth | |
| 700 | 1 | |a Goadsby, Peter J |e investigator |4 oth | |
| 700 | 1 | |a Schwedt, Todd J |e investigator |4 oth | |
| 700 | 1 | |a Robbins, Matthew S |e investigator |4 oth | |
| 700 | 1 | |a Ailani, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Tepper, Stewart J |e investigator |4 oth | |
| 700 | 1 | |a Halker Singh, Rashmi B |e investigator |4 oth | |
| 700 | 1 | |a Harriott, Andrea M |e investigator |4 oth | |
| 700 | 1 | |a Lay, Christine |e investigator |4 oth | |
| 700 | 1 | |a Nahas, Stephanie J |e investigator |4 oth | |
| 700 | 1 | |a Powers, Scott W |e investigator |4 oth | |
| 700 | 1 | |a Rosen, Noah |e investigator |4 oth | |
| 700 | 1 | |a Starling, Amaal J |e investigator |4 oth | |
| 700 | 1 | |a Wells, Rebecca |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Headache |d 1961 |g 64(2024), 4 vom: 15. Apr., Seite 333-341 |w (DE-627)NLM000375330 |x 1526-4610 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:333-341 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/head.14692 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2024 |e 4 |b 15 |c 04 |h 333-341 | ||